drugset / Trial / NCT01212367
Intrapleural Gene Transfer for Pleural Mesothelioma
Phase 1
Completed
13 enrolled
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This research will study how to activate the immune system by using gene transfer. Gene transfer involves inserting a specially designed gene into cancer cells. A gene is a part of the genetic code that instructs the cells of our bodies to produce specific compounds (proteins) important for the makeup or function of the cell. The study hypothesis is that repeated doses of SCH 721015 given over a three day interval would result in gene transfer.
Timeline
- Start
- 2009-02
- Primary completion
- 2015-05
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nadofaragene Firadenovec | Unknown | 3e+11 vg | Intrathecal |
| Subject | Nadofaragene Firadenovec | Unknown | 1e+12 vg | Intrathecal |